UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043374
Receipt number R000049523
Scientific Title A study for safety evaluation of excessive intake of Lactic acid bacterium-powder
Date of disclosure of the study information 2021/02/21
Last modified on 2021/08/21 16:31:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study for safety evaluation of excessive intake of Lactic acid bacterium-powder

Acronym

Safety evaluation of excessive intake of Lactic acid bacterium-powder

Scientific Title

A study for safety evaluation of excessive intake of Lactic acid bacterium-powder

Scientific Title:Acronym

Safety evaluation of excessive intake of Lactic acid bacterium-powder

Region

Japan


Condition

Condition

None

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the safety of the excessive intake of Lactic acid bacterium-powder

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Adverse event and side effect

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of Lactic acid bacterium-powder for 4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1)Subjects aged more than 20 years, less than 65 years.
2)Subjects who received an enough explanation of the test objectives and detail, who have consent ability, who are willing to participate with well understandings and who have signed the informed consent document.

Key exclusion criteria

1)Subjects who have a history of serious illness.
2)Subjects who are under treatment with medication for lifestyle-related disease (diabetes, hypertension, dyslipidemia).
3)Subjects who have digestive tract diseases that affect digestion and absorption, and have had a history of gastrointestinal surgery (excluding appendicitis).
4)Subjects who have a medical history of serious allergy to medicine, food and pollen.
5)Subjects who are pregnant or under lactation, or who is expected to be pregnant during the study.
6)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism.
7)Subjects who are planning to participate in other clinical studies.
8)Subjects who are judged unsuitable for participating in this study by the principal investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Masahiko
Middle name
Last name Tokushima

Organization

Maebashi North Hospital

Division name

Director

Zip code

371-0054

Address

692 Shimohosoi-machi,Maebashi-shi,Gumma

TEL

027-235-3333

Email

sagawa@mc-connect.co.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Yoshikawa

Organization

KSO Corporation

Division name

Sales department

Zip code

105-0023

Address

1-9-7, Shibaura, Minato-ku, Tokyo The 7th floor of Shibaura omodaka building

TEL

03-3452-7733

Homepage URL


Email

yoshikawa@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

Morinaga Milk Industry Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Kobuna Orthopedics Clinic

Address

5-656-17 Joto-machi, Maebashi-shi, Gumma

Tel

027-212-5608

Email

sagawa@mc-connect.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人 前橋北病院(群馬県)/ Maebashi North Hospital (Gunma)


Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 02 Month 12 Day

Date of IRB

2021 Year 02 Month 18 Day

Anticipated trial start date

2021 Year 02 Month 22 Day

Last follow-up date

2021 Year 04 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 02 Month 19 Day

Last modified on

2021 Year 08 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049523


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name